We were instructed by two global pharmaceutical companies, H. Lundbeck A/S and Takeda Pharmaceuticals, to defend an opposition filed against their patent to an antidepressant medication vortioxetine (marketed as Brintellix).
With a need to balance scientific invention with commercial objectives, the company needed IP advisers who could both gain the confidence of its scientists and engineers and help it meet its commercial objectives.
BG Research Ltd and sister company BioGene Ltd are innovative SMES in diagnostics technology, encompassing both biotechnology and biology along with electrical and mechanical aspects.
As the foundation of AstraZeneca’s respiratory biologics portfolio, targeting the underlying causes of respiratory illnesses, Fasenra® (benralizumab) is a crucial product for this multinational client.
In 2018, we preserved the European patent in a successful defence in EPO opposition proceedings filed by two generic pharmaceutical manufacturers.
In one of the most significant patent cases of 2018/19, we fielded a 15-strong multidisciplinary team of specialist IP solicitors and patent attorneys to secure a global settlement for Alnylam Pharmaceuticals Inc.
Our biotech team brought to bear their deep scientific understanding and legal experience in patent drafting and global filing and prosecution strategy to secure commercially-focussed patent protection.
The patents and design registrations successfully obtained by the team at Potter Clarkson put the necessary IP protection in place to enable Sanandco to commercialise its product in its most commercially important territories.
We have been working with Alligator Bioscience AB, a Swedish SME specialising in the development of antibody-based therapeutics for cancer treatment since the company’s formation in 2001.